IFN-γ-inducing factor/IL-18 administration mediates IFN-γ- and IL-12- independent antitumor effects

Journal of Immunology

Volumn 160, Issue 4, 1998, Pages 1742-1749

  Osaki, Tadashi ^a   Péron, Jean Marie ^a   Cai, Quan ^a   Okamura, Haruki ^b   Robbins, Paul D ^a   Kurimoto, Masashi ^c   Lotze, Michael T ^a   Tahara, Hideaki ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GANGLIOSIDE ANTIBODY; GANGLIOTETRAOSYLCERAMIDE; INTERFERON INDUCING AGENT; INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FIBROSARCOMA; GENE DISRUPTION; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FIBROSARCOMA; G(M1) GANGLIOSIDE; GENE DELETION; GROWTH INHIBITORS; IMMUNE SERA; INJECTIONS, INTRAPERITONEAL; INTERFERON INDUCERS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-18; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; SARCOMA, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 2642674449     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ciolli, V., L. Gabriele, P. Sestili, F. Verano, E. Proietti, I. Gresser, U. Testa, E. Montesoro, D. Bulgarini, G. Mariani, and F. Belardelli. 1991. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases. J. Exp. Med. 173:313.
2. Rosenberg, S. A., J. J. Mulè, P. J. Spiess, C. M. Reichert, and S. L. Schwarz. 1985. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J. Exp. Med. 161:1169.
3. Bosco, M., M. Giovarelli, M. Forni, A. Modesti, S. Scarpa, L. Masuelli, and G. Forni. 1990. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J. Immunol. 145:3136.
4. Brunda, M. J., V. Sulich, and D. Belantoni. 1987. The anti-tumor effect of recombinant interferon alpha or gamma is influenced by tumor location. Int. J. Cancer 40:807.
5. Sayers, T. J., T. A. Wiltrout, K. McCormick, C. Husted, and R. H. Wiltrout. 1990. Antitumor effects of α-interferon and γ-interferon on murine renal cancer (Renca) in vitro and in vivo. Cancer Res. 50:5414.
6. Giovarelli, M., F. Cofano, A. Vecchi, M. Forni, S. Landolfo, and G. Forni. 1986. Interferon-activated tumor inhibition in vivo: small amounts of interferon-gamma inhibit tumor growth by eliciting host systemic immunoreactivity. Int. J. Cancer 37:141.
7. Mulè, J. J., A. Asher, J. McIntosh, R. L. Afreniere, E. Shiloni, A. Lefor, C. M. Reichert, and S. A. Rosenberg. 1988. Antitumor effect of recombinant tumor necrosis factor-α against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol. Immunother. 26:202.
8. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
9. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
10. Noguchi, Y., E. C. Richards, Y.-T. Chen, and L. J. Old. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
11. + αβ T cells with intermediate TCR induced in the liver of mice by IL-12. J. Immunol. 154:4333.
12. Brunda, M. J., L. Luistro, L. Rumennik, R. B. Wright, J. M. Wigginton, R. H. Wiltrout, J. A. Hendrzak, and A. V. Palleroni. 1996. Interleukin-12: murine models of a potent antitumor agent. Ann. NY Acad. Sci. 795:266.
13. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87:581.
14. Tannenbaum, C. S., N. Wicher, D. Armstrong, R. Tubbs, J. Finke, R. M. Bukowski, and T. A. Hamilton. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156:693.
15. Angiolillo, A. L., C. Sgadari, and G. Tosato. 1996. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin 12. Ann. NY Acad. Sci. 795:158.
16. Atkins, M. B., M. J. Robertson, M. Gordon, M. T. Lotze, M. DeCoste, J. S. DuBois, J. Ritz, A. B. Sandler, H. D. Edington, P. D. Garzone, J. W. Mier, C. M. Canning, L. Battiato, H. Tahara, and M. L. Sherman. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3:409.
17. Okamura, H., H. Tsutusui, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, K. Akita, M. Namba, F. Tanabe, K. Konishi, F. Shigeharu, and M. Kurimoto. 1995. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378:88.
18. Gu, Y., K. Kuida, H. Tsutsui, G. Ku, K. Hsiao, M. A. Fleming, N. Hayashi, K. Higashino, H. Okamura, K. Nakanishi, M. Kurimoto, T. Tanimoto, R. A. Flavell, V. Sato, M. W. Harding, and D. J. Livingston. 1997. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 275:206.
19. Akita, K., S. Ushio, T. Ohtsuki, T. Tanimoto, M. Ikeda, and M. Kurimoto. 1997. Comparison between the biological and biochemical aspects of IL-18 (IFN-gamma-inducing factor) and IL-1β. Proc. Am. Assoc. Cancer Res. 38:357.
20. Micallef, M. J., T. Ohtsuki, K. Kohno, F. Tanabe, S. Ushio, M. Namba, T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, and M. Kurimoto. 1996. Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur. J. Immunol. 26:1647.
21. Kohno, K., J. Kataoka, T. Ohtsuki, Y. Suemoto, I. Okamoto, M. Usui, M. Ikeda, and M. Kurimoto. 1997. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J. Immunol. 158:1541.
22. Suzuki, T., H. Tahara, S. Narula, K. W. Moore, P. D. Robbins, and M. T. Lotze. 1995. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J. Exp. Med. 182:477.
23. Magram, J., S. E. Connaughton, R. R. Warrier, D. M. Carvajal, C. Wu, J. Ferrante, C. Stewart, U. Sarmiento, D. A. Faherty, and M. K. Gately. 1996. IL-12-deficient mice are defective in IFN-γ production and type 1 cytokine responses. Immunity 4:471.
24. Sgadari, C., A. L. Angiolillo, B. W. Cherney, S. E. Pike, J. M. Fareber, L. G. Koniaris, P. Vanguri, P. R. Burd, N. Sheikh, G. Gupta, J. Teruya-Feldstien, and G. Tosato. 1996. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA 93:1791.
25. Dalton, D. K., S. Pitts-Meek, S. Keshav, I. S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 259:1739.
26. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827.
27. Manetti, R., P. Parronchi, M. G. Giudizi, M.-P. Piccinni, E. Maggi, G. Trinchieri, and S. Romangnani. 1993. Natural killer cell stimulatory factor (interleukin 12 (IL-12)) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199.
28. Luster, A. D., J. Unkeless, and J. Ravetch. 1985. γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315:672.
29. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari, H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human interferon-γ-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182:155.
30. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, S. B. Morris, M. D. Burdick, M. C. Glass, D. T. Taub, M. D. Ianntettoni, R. I. Whyte, and R. M. Strieter. 1996. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184:981.
31. Trinchieri, G. 1994. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008.
32. Micallef, M. J., K. Yoshida, S. Kawai, T. Hanaya, K. Kohno, S. Arai, T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, and M. Kurimoto. 1997. In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol. Immunother. 43:361.
33. Dao, T., K. Ohashi, T. Kayano, M. Kurimoto, and H. Okamura. 1996. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell. Immunol. 173:230.